Join the Nirmatrelvir / ritonavir group to help and get support from people like you.
Nirmatrelvir / ritonavir News
Extended Nirmatrelvir/Ritonavir Beneficial for Some With Long COVID
WEDNESDAY, Jan. 8, 2025 – Extended-course nirmatrelvir/ritonavir yields a meaningful reduction in symptoms for some patients with long COVID, but not all benefits persist, according to a case series...
Postexposure Prophylaxis With Nirmatrelvir-Ritonavir Does Not Cut COVID-19 Infection
THURSDAY, July 18, 2024 – Postexposure prophylaxis with nirmatrelvir-ritonavir for five or 10 days does not reduce the risk for symptomatic severe acute respiratory syndrome coronavirus 2...
Nirmatrelvir-Ritonavir No Aid for Long COVID Symptoms
MONDAY, June 10, 2024 – A 15-day course of nirmatrelvir-ritonavir (NMV/r) is safe but does not demonstrate a significant benefit for improving postacute sequelae of SARS-CoV-2 infection (PASC)...
Extended Course of Paxlovid Adds No Benefit for Those With Long COVID
FRIDAY, June 7, 2024 – An extended course of the antiviral drug Paxlovid won’t ease a person’s Long COVID symptoms, a new study finds. People who took Paxlovid for 15 days – three times as long as i...
FDA Approves Paxlovid (nirmatrelvir tablets and ritonavir tablets) for Adult Patients at High Risk of Progression to Severe COVID-19
NEW YORK--(BUSINESS WIRE) May 25, 2023 – Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) approved Paxlovid™ (nirmatrelvir tablets and ritonavir tablets) for t...